Just some questions for more experienced investors.
1. The composition of the top shareholders has changed dramatically over 12 months from a mix of funds to a basket case of institutional investors presumably even more so after the cap raise so it's extremely loose held.
2. Logically, if the results or preliminary non-market findings were good you'd see fewer institutionals on board (I.e. a couple investors taking on more risk).
3. I still don't really understand why they would do a capital raise before results given that assay results are only weeks away.
Cheers
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.80M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $30.16K | 7.387M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 85 | 49580103 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 17688676 | 19 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RDN (ASX) Chart |